(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 45.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.25%.
Arcutis Biotherapeutics's revenue in 2024 is $106,394,000.On average, 1 Wall Street analysts forecast ARQT's revenue for 2024 to be $12,864,176,960, with the lowest ARQT revenue forecast at $12,864,176,960, and the highest ARQT revenue forecast at $12,864,176,960. On average, 1 Wall Street analysts forecast ARQT's revenue for 2025 to be $26,461,025,315, with the lowest ARQT revenue forecast at $26,461,025,315, and the highest ARQT revenue forecast at $26,461,025,315.
In 2026, ARQT is forecast to generate $38,626,218,253 in revenue, with the lowest revenue forecast at $38,626,218,253 and the highest revenue forecast at $38,626,218,253.